These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8107635)

  • 21. Incentives in the Medicare prescription drug benefit.
    Natl Bur Econ Res Bull Aging Health; 2006; (15):1-2. PubMed ID: 16805056
    [No Abstract]   [Full Text] [Related]  

  • 22. Health insurance oversight issue brief: mandated benefits: off-label drug coverage requirements: year end report--2004.
    Plaza CI
    Issue Brief Health Policy Track Serv; 2004 Dec; ():1-9. PubMed ID: 15726733
    [No Abstract]   [Full Text] [Related]  

  • 23. [TLV meets criticism: costs of antihypertensive agents can and should be reduced].
    Edling A; Löfmark R; Vinge E; Carlsson P; André M; Melltorp G; Edhag O; Dahlqvist R; Andersson I; Magnusson D
    Lakartidningen; 2008 Sep 17-23; 105(38):2592-3. PubMed ID: 18846865
    [No Abstract]   [Full Text] [Related]  

  • 24. Has the use of disease-modifying anti-rheumatic drugs changed as a consequence of controlled access to high-cost biological agents through the Pharmaceutical Benefits Scheme?
    Lu CY; Williams KM; Day RO
    Intern Med J; 2007 Sep; 37(9):601-6. PubMed ID: 17542999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medicare and TRICARE.
    Politi E
    Issue Brief Cent Medicare Educ; 2002; 3(2):1-6. PubMed ID: 11878352
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PBS reform - a missed opportunity?
    de Boer R
    Aust Health Rev; 2009 May; 33(2):176-85. PubMed ID: 19563306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia.
    McManus P; Birkett DJ; Dudley J; Stevens A
    Pharmacoepidemiol Drug Saf; 2001; 10(4):295-300. PubMed ID: 11760489
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Private, individual drug coverage in the current Medicare market.
    Boccuti C; Moon M
    Policy Brief Commonw Fund; 2003 Oct; (679):1-10. PubMed ID: 14562796
    [No Abstract]   [Full Text] [Related]  

  • 29. Copayments for medications. Final rule.
    Department of Veterans Affairs
    Fed Regist; 2001 Dec; 66(235):63449-51. PubMed ID: 11778627
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Medicare prescription drug benefit: focusing on coverage and cost.
    Cubanski J; Kline J
    Issue Brief (Commonw Fund); 2002 Apr; (538):1-6. PubMed ID: 11993504
    [No Abstract]   [Full Text] [Related]  

  • 31. Finance, pharmaceuticals issue brief: mandated benefits: clinical trial coverage requirements: year end report-2003.
    Plaza CI
    Issue Brief Health Policy Track Serv; 2003 Dec; ():1-6. PubMed ID: 14870752
    [No Abstract]   [Full Text] [Related]  

  • 32. [Discontinuation of subsidizing of certain antihypertensive agents is not well thought-out].
    Berggren B; Lindström T; Nyström F; Cizinsky S; Weiss L; Willenheimer R
    Lakartidningen; 2008 Aug 27-Sep 2; 105(35):2345-6. PubMed ID: 18831442
    [No Abstract]   [Full Text] [Related]  

  • 33. Aspects of the Pharmaceuticals Benefits Scheme.
    Baume P
    J Qual Clin Pract; 2001 Sep; 21(3):89-91. PubMed ID: 11892832
    [No Abstract]   [Full Text] [Related]  

  • 34. Barrier to trade or barrier to profit? Why Australia's Pharmaceutical Benefits Scheme worries U.S. drug companies.
    Hamilton C; Lokuge B; Denniss R
    Yale J Health Policy Law Ethics; 2004; 4(2):373-85. PubMed ID: 15536919
    [No Abstract]   [Full Text] [Related]  

  • 35. Chronic conditions and disabilities: trends and issues for private drug plans.
    Boccuti C; Moon M; Dowling K
    Policy Brief Commonw Fund; 2003 Oct; (680):1-10. PubMed ID: 14562797
    [No Abstract]   [Full Text] [Related]  

  • 36. Drug coverage in Canada: gaps and opportunities.
    Clement F; Memedovich KA
    J Psychiatry Neurosci; 2018 May; 43(3):148-150. PubMed ID: 29688870
    [No Abstract]   [Full Text] [Related]  

  • 37. [Non-biased (?) blood pressure experts criticize LFN].
    Hernborg A
    Lakartidningen; 2008 Sep 17-23; 105(38):2593-4. PubMed ID: 18846866
    [No Abstract]   [Full Text] [Related]  

  • 38. The caring profession: paediatricians and altruism.
    Isaacs D
    J Paediatr Child Health; 2009 Oct; 45(10):553. PubMed ID: 19825022
    [No Abstract]   [Full Text] [Related]  

  • 39. Using clinical evidence to manage pharmacy benefits: experiences of six states.
    Bergman D; Hoadley J; Kaye N; Crowley J; Hostetter M
    Issue Brief (Commonw Fund); 2006 Mar; (899):1-14. PubMed ID: 16562357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of copayments and safety nets on PBS expenditure.
    Sweeny K
    Aust Health Rev; 2009 May; 33(2):215-30. PubMed ID: 19563310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.